Clinical Significance of Low Expression of LncRNA CASC15 in Acute Myeloid Leukemia with NPM1 Mutations.
10.19746/j.cnki.issn.1009-2137.2022.03.002
- Author:
Pei-Hui XIA
1
;
Zi-Jun XU
1
;
Ye JIN
2
;
Ji-Chun MA
1
;
Xiang-Mei WEN
1
;
Qian YUAN
2
;
Jia-Yan LENG
2
;
Jun QIAN
3
;
Jiang LIN
4
Author Information
1. Laboratory Center, Affiliated People's Hospital of Jiangsu University,Zhenjiang 212002, Jiangsu Province, China，Zhenjiang Clinical Research Center of Hematology,Zhenjiang 212002, Jiangsu Province, China.
2. Zhenjiang Clinical Research Center of Hematology,Zhenjiang 212002, Jiangsu Province, China，Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu Province, China.
3. Zhenjiang Clinical Research Center of Hematology,Zhenjiang 212002, Jiangsu Province, China，Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu Province, China,E-mail: qianjun0007@hotmail.com.
4. Laboratory Center, Affiliated People's Hospital of Jiangsu University,Zhenjiang 212002, Jiangsu Province, China，Zhenjiang Clinical Research Center of Hematology,Zhenjiang 212002, Jiangsu Province, China,E-mail: 2651329493@qq.com.
- Publication Type:Journal Article
- Keywords:
CASC15;
NPM1;
acute myeloid leukemia;
methylation;
prognosis
- MeSH:
Humans;
Leukemia, Myeloid, Acute/metabolism*;
Mutation;
Nuclear Proteins/genetics*;
Nucleophosmin/genetics*;
Prognosis;
RNA, Long Noncoding/genetics*
- From:
Journal of Experimental Hematology
2022;30(3):659-670
- CountryChina
- Language:Chinese
-
Abstract:
AbstractObjective: To identify the expression and methylation patterns of lncRNA CASC15 in bone marrow (BM) samples of acute myeloid leukemia (AML) patients, and further explore its clinical significance.
METHODS:Eighty-two de novo AML patients and 18 healthy donors were included in the study. Meanwhile, seven public datasets from Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) were included to confirm the expression and methylation data of CASC15. Receiver operating characteristic (ROC) curve analysis was applied to determine the discriminative capacity of CASC15 expression to identify AML. The patients were divided into CASC15high group and CASC15low group by X-tile method, and the prognostic value of CASC15 was identified by Kaplan-Meier method and univariate and multivariate Cox regression analysis.
RESULTS:The expression level of CASC15 was significantly decreased in BM cells of AML patients compared with healthy donors (P<0.001). ROC curve analysis suggested that CASC15 expression might be a potential biomarker to discriminate AML from controls. The expression of CASC15 was high at the early stage of hematopoiesis, and reached a peak at the stage of multipotent progenitors differentiation, then decreased rapidly, and was at a range of low level fluctuations in the subsequent process. Among FAB subtypes, CASC15 expression in M0 was significantly higher than that in M1-M7. Clinically, CASC15low patients were more likely to have NPM1 mutations than CASC15high patients (P=0.048), while CASC15high patients had a significantly higher frequency of IDH1 and RUNX1 mutations (P=0.021 and 0.014, respectively). Moreover, CASC15low group had a shorter overall survival (OS) in patients with NPM1 mutations. Furthermore, multivariate analysis confirmed that CASC15 expression was a significant independent risk factor for OS in NPM1 mutated AML patients. In addition, CASC15 methylation level in BM samples of AML patients was significantly decreased compared with healthy donors. Patients with CASC15 high methylation had poor OS and disease-free survival.
CONCLUSION:The expression of CASC15 is decreased in AML, and low CASC15 expression may predict adverse prognosis in AML patients with NPM1 mutations. Moreover, CASC15 methylation level in AML is significantly decreased, and high CASC15 methylation may predict poor prognosis in AML.
